TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19029264

Group type: EXPERIMENTAL
Intervention: Minimized extracorporeal circulation system (MECC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Usual pump (control group)
Number of subjects: 80
Study: 16183654

Group type: EXPERIMENTAL
Intervention: Postcards intervention (eight postcards over 12 months) along with standard treatment
Number of subjects: 772

Group type: COMPARATOR
Intervention: Standard treatment alone
Number of subjects: 772
Study: 12190164

Group type: EXPERIMENTAL
Intervention: FDG-PET
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Hydro-MRI
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: Granulocyte scintigraphy
Number of subjects: 59

Group type: COMPARATOR
Intervention: Control (Irritable bowel syndrome and tumor patients)
Number of subjects: 59
Study: 10072215

Group type: EXPERIMENTAL
Intervention: Tirofiban followed by randomization to invasive strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invasive strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conservative strategy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Health-related quality of life assessment using the Seattle Angina Questionnaire and Health Utilities Index
Number of subjects: 0
Study: 7793189

Group type: EXPERIMENTAL
Intervention: Propofol mixed with prilocaine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propofol and lidocaine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Propofol with prilocaine+lidocaine (equal amounts)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Propofol and saline
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Ketorolac (30 mg)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Saline (equal volume to ketorolac)
Number of subjects: 48
Study: 1795055

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate (CHX) solution
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: 0.025% amine‐stannous fluoride (AmF + SnF) solution
Number of subjects: 51

Group type: COMPARATOR
Intervention: 0.05% sodium fluoride (F) solution
Number of subjects: 51
Study: 7236870

Group type: COMPARATOR
Intervention: 160 mg oral dose of 'Inderal' tablet (conventional formulation)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sustained release formulation 'Inderal' LA
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clinical trial sustained release formulation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Sustained release formulations (both)
Number of subjects: 12
Study: 30576441

Group type: EXPERIMENTAL
Intervention: 2% O2
Number of subjects: 1955

Group type: COMPARATOR
Intervention: 5% O2 (control)
Number of subjects: 1955
Study: 28719827

Group type: EXPERIMENTAL
Intervention: Transcutaneous VNS (tVNS) during extinction phase
Number of subjects: 42

Group type: COMPARATOR
Intervention: Sham stimulation during extinction phase
Number of subjects: 42
Study: 25943394

Group type: EXPERIMENTAL
Intervention: Metformin (with supplemental insulin if required)
Number of subjects: 222

Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 222
Study: 23052515

Group type: EXPERIMENTAL
Intervention: Combined general-epidural anesthesia (group GE)
Number of subjects: 45

Group type: COMPARATOR
Intervention: General anesthesia (group G)
Number of subjects: 45
Study: 21741089

Group type: EXPERIMENTAL
Intervention: Biphasic insulin aspart 70/30 (BIAsp 30)
Number of subjects: 716
Study: 19095875

Group type: EXPERIMENTAL
Intervention: 200 mg tramadol
Number of subjects: 102

Group type: COMPARATOR
Intervention: 4 mL saline (control group)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 100 mg tramadol and 2 mL saline (TL group)
Number of subjects: 102
Study: 15844317

Group type: EXPERIMENTAL
Intervention: Lornoxicam
Number of subjects: 39

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 39
Study: 11807305

Group type: EXPERIMENTAL
Intervention: HIV-1 genotyping
Number of subjects: 326

Group type: EXPERIMENTAL
Intervention: Expert advice
Number of subjects: 326

Group type: COMPARATOR
Intervention: No genotyping
Number of subjects: 326
Study: 10072411

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B
Number of subjects: 687

Group type: COMPARATOR
Intervention: Conventional amphotericin B
Number of subjects: 687
Study: 8749628

Group type: EXPERIMENTAL
Intervention: Pentagastrin
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: Glutamic acid
Number of subjects: 19

Group type: COMPARATOR
Intervention: Baseline period
Number of subjects: 19
Study: 2024815

Group type: EXPERIMENTAL
Intervention: Influenza A/Bethesda/1/85 (H3N2)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study: 7029292

Group type: COMPARATOR
Intervention: Adjuvant chemotherapy with Adriamycin and cyclophosphamide (Cytoxan) in soft tissue sarcomas
Number of subjects: 105

Group type: COMPARATOR
Intervention: High-dose methotrexate following surgery in osteogenic sarcoma
Number of subjects: 105

Group type: COMPARATOR
Intervention: Frequent screening for pulmonary metastases and surgical resection of these metastases in osteogenic sarcoma
Number of subjects: 105
Study: 31464343

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (diet and exercise)
Number of subjects: 360
Study: 31144258

Group type: EXPERIMENTAL
Intervention: McGrath MAC videolaryngoscope (MVL)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Pentax Airway Scope (PVL)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Macintosh direct laryngoscope (DL)
Number of subjects: 120
Study: 27596027

Group type: EXPERIMENTAL
Intervention: Web-based physiotherapy (8 weeks, twice per week)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 24
Study: 25245489

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium 100 mg once daily
Number of subjects: 368

Group type: EXPERIMENTAL
Intervention: Pentosan polysulfate sodium 100 mg three times daily
Number of subjects: 368

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 368
Study: 23588794

Group type: EXPERIMENTAL
Intervention: Subcutaneous sumatriptan injection (6 mg)
Number of subjects: 18
Study: 21301814

Group type: EXPERIMENTAL
Intervention: 50 mg D-cycloserine (DCS)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: 50 mg D-cycloserine (DCS) with partial smoking
Number of subjects: 48

Group type: COMPARATOR
Intervention: Placebo with partial smoking
Number of subjects: 48
Study: 18973950

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT) with intravenous verteporfin at 6 mg/m² body surface, laser beam applied at radiant exposure 50 J/cm² for 83 seconds, 1 to 4 treatments at 12-week intervals over 1 year.
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 31
Study: 17479927

Group type: EXPERIMENTAL
Intervention: Elaborative encoding
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rote rehearsal
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Verbalisation during encoding
Number of subjects: 0
Study: 15198886

Group type: EXPERIMENTAL
Intervention: Stroke Unit (SU)
Number of subjects: 392

Group type: COMPARATOR
Intervention: General Ward (GW)
Number of subjects: 392
Study: 11770871

Group type: EXPERIMENTAL
Intervention: Statin treatment for > or = 6 months before hospital admission
Number of subjects: 1000
Study: 9674006

Group type: EXPERIMENTAL
Intervention: Diclofenac 0.1%
Number of subjects: 26

Group type: COMPARATOR
Intervention: Prednisolone acetate 1%
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study: 8077738

Group type: COMPARATOR
Intervention: 1 day of parenteral clindamycin (standard prophylaxis)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 1 day of topical clindamycin
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 days of topical clindamycin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 1 day of topical amoxicillin plus clavulanate/ticarcillin plus clavulanate
Number of subjects: 0
Study: 2642629

Group type: EXPERIMENTAL
Intervention: Oral milrinone
Number of subjects: 750

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 750
Study: 1103330

Group type: EXPERIMENTAL
Intervention: Nitrazepam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31228055

Group type: EXPERIMENTAL
Intervention: ASM-Enhanced Collaborative Care (CSM)
Number of subjects: 294

Group type: COMPARATOR
Intervention: Automated Self-management (ASM)
Number of subjects: 294
Study: 28719305

Group type: EXPERIMENTAL
Intervention: Price reduction ($0.11‐$0.56 per chlorine bottle)
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Price reduction
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Monthly visits from sales agents
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Price discounts
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Lowest price and conducting visits
Number of subjects: 1798

Group type: EXPERIMENTAL
Intervention: Slightly raising the retail price and not conducting visits
Number of subjects: 1798
Study: 26272768

Group type: EXPERIMENTAL
Intervention: Rolapitant (180 mg dose)
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Active control (placebo)
Number of subjects: 1369

Group type: EXPERIMENTAL
Intervention: Rolapitant
Number of subjects: 1369

Group type: COMPARATOR
Intervention: Active control
Number of subjects: 1369
Study: 22719016

Group type: EXPERIMENTAL
Intervention: 4 mg of chlorpheniramine
Number of subjects: 16

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 200 mg of caffeine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: 4 mg of chlorpheniramine-200 mg of caffeine
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: chlorpheniramine-placebo
Number of subjects: 16
Study: 21754985

Group type: EXPERIMENTAL
Intervention: Valproic acid (VPA) and L-carnitine for 12 months
Number of subjects: 33
Study: 18641770

Group type: EXPERIMENTAL
Intervention: 10% manitol (M Group, n=40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Polyethyleneglycol (PEG Group, n=40)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 80
Study: 16307157

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 28

Group type: COMPARATOR
Intervention: Control group (non-exercising)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Comparison of control and resistance training groups
Number of subjects: 28
Study: 11782819

Group type: EXPERIMENTAL
Intervention: 20 mg valdecoxib twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg valdecoxib twice daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9653559

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Conventional appendectomy
Number of subjects: 54
Study: 8590611

Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT) 100 mg, PO, tid
Number of subjects: 24

Group type: COMPARATOR
Intervention: Standard detoxification therapy
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Phenytoin (PHT) 50-100 mg, bid-tid after acute withdrawal
Number of subjects: 24
Study: 2492178

Group type: COMPARATOR
Intervention: Bilateral myringotomy and no additional treatment (group 1)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes (group 2)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Adenoidectomy and myringotomy (group 3)
Number of subjects: 578

Group type: EXPERIMENTAL
Intervention: Adenoidectomy and tympanostomy tubes (group 4)
Number of subjects: 578
Study: 1091151

Group type: EXPERIMENTAL
Intervention: Adenine arabinoside 20 mg/kg/day intravenous infusions for seven days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Adenine arabinoside
Number of subjects: 0
Study: 30895579

Group type: EXPERIMENTAL
Intervention: Video laryngoscopy
Number of subjects: 27

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 27
Study: 29336823

Group type: EXPERIMENTAL
Intervention: Positive control material for CT and NG testing using GeneXpert (Xpert) assay.
Number of subjects: 89
Study: 27281720

Group type: EXPERIMENTAL
Intervention: Intraneural injection (group INTRA)
Number of subjects: 88

Group type: COMPARATOR
Intervention: Subparaneural injection (group SUBPARA)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 88
Study: 24804714

Group type: EXPERIMENTAL
Intervention: Hearing conservation intervention for rural students
Number of subjects: 392
Study: 22809586

Group type: EXPERIMENTAL
Intervention: Hypofractionated radiotherapy (5 fractions of 5.7 or 6.0 Gy over 5 weeks)
Number of subjects: 915

Group type: COMPARATOR
Intervention: Standard fractionation (control group)
Number of subjects: 915
Study: 20546592

Group type: EXPERIMENTAL
Intervention: Physical coordination training
Number of subjects: 758

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural theory-based training
Number of subjects: 758

Group type: COMPARATOR
Intervention: Reference group
Number of subjects: 758
Study: 18697216

Group type: EXPERIMENTAL
Intervention: LAM (arm 1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: TDF (arm 2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: LAM/TDF (arm 3)
Number of subjects: 36
Study: 15850631

Group type: EXPERIMENTAL
Intervention: Amodiaquine
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Amodiaquine + sulfadoxine‐pyrimethamine
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Amodiaquine + artesunate
Number of subjects: 1811

Group type: EXPERIMENTAL
Intervention: Artemether‐lumefantrine
Number of subjects: 1811
Study: 12530594

Group type: EXPERIMENTAL
Intervention: Exposure to PCBs and PCDFs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Follow-up after 9 months
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Serum PCBs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Follow-up serum PCB levels
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Serum toxic equivalency (TEQ) for total PCDDs and PCDFs
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Short-term health effects
Number of subjects: 60
Study: 9601827

Group type: EXPERIMENTAL
Intervention: Haemaccel
Number of subjects: 20

Group type: COMPARATOR
Intervention: Ringer's lactate
Number of subjects: 20
Study: 8026195

Group type: EXPERIMENTAL
Intervention: PGE1 (30 ng/kg/min)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 2542427

Group type: EXPERIMENTAL
Intervention: Continuous subcutaneous insulin infusion (CSII) therapy
Number of subjects: 11

Group type: COMPARATOR
Intervention: Conventional insulin therapy (CIT)
Number of subjects: 11
Study: 31139982

Group type: EXPERIMENTAL
Intervention: Laparoscopic appendectomy (LA)
Number of subjects: 126

Group type: COMPARATOR
Intervention: Open appendectomy (OA)
Number of subjects: 126
Study: 28520672

Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 62

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 62
Study: 25359302

Group type: EXPERIMENTAL
Intervention: HHV-8 seropositivity
Number of subjects: 630

Group type: COMPARATOR
Intervention: Control group (no HHV-8 seropositivity)
Number of subjects: 630
Study: 23725996

Group type: EXPERIMENTAL
Intervention: Fast walkers (6MWTD >128.5 meters)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Slow walkers (6MWTD below median 128.5 meters)
Number of subjects: 484

Group type: EXPERIMENTAL
Intervention: Unable to walk
Number of subjects: 484

Group type: COMPARATOR
Intervention: Slow walkers
Number of subjects: 484

Group type: COMPARATOR
Intervention: Fast walkers
Number of subjects: 484
Study: 21839983

Group type: EXPERIMENTAL
Intervention: Conventional physiotherapy + Aerobic exercise (intervention group)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional physiotherapy (control group)
Number of subjects: 46
Study: 20088414

Group type: EXPERIMENTAL
Intervention: Electroacupuncture under continuous traction in prone position (Group A)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Electroacupuncture after supine position traction (Group B)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Electroacupuncture only (Group C)
Number of subjects: 119
Study: 17224222

Group type: EXPERIMENTAL
Intervention: PNB classification by nine independent observers
Number of subjects: 100
Study: 15485437

Group type: EXPERIMENTAL
Intervention: Digitalis and beta-blocker during isoproterenol infusion
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no additional treatment)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Slow pathway ablation (RFA)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Isoproterenol infusion
Number of subjects: 40
Study: 11507585

Group type: EXPERIMENTAL
Intervention: Patching
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Atropine
Number of subjects: 64

Group type: COMPARATOR
Intervention: Patching and Atropine
Number of subjects: 64
Study: 9753263

Group type: EXPERIMENTAL
Intervention: Cisapride 20 mg twice daily for six months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Partial posterior fundoplication without cisapride
Number of subjects: 34
Study: 7826831

Group type: EXPERIMENTAL
Intervention: 97 mg amoxycillin sodium (0.25 mmol)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 3103 mg amoxycillin sodium (8 mmol)
Number of subjects: 6
Study: 30197311

Group type: EXPERIMENTAL
Intervention: Verapamil injection (2 mL) around the anastomosis site before and after surgery (2, 4, 6, 8, and 10 weeks after surgery)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (anastomosis surgery only)
Number of subjects: 32
Study: 27185164

Group type: EXPERIMENTAL
Intervention: FP/FORM (100/10 µg b.i.d.)
Number of subjects: 211

Group type: COMPARATOR
Intervention: FP/SAL (100/50 µg b.i.d.)
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: FP/FORM
Number of subjects: 211

Group type: COMPARATOR
Intervention: FP/FORM and FP/SAL
Number of subjects: 211
Study: 24190232

Group type: EXPERIMENTAL
Intervention: MSUS-guided injection of 40 mg of methylprednisolone acetate (Group 2, n = 59)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Palpation-guided injection (Group 1, n = 66)
Number of subjects: 100
Study: 22441150

Group type: EXPERIMENTAL
Intervention: Holmium laser lithotripsy (LL) using a 550‐μm fiber
Number of subjects: 80

Group type: COMPARATOR
Intervention: Pneumatic lithotripsy (PL) using the Swiss Lithoclast
Number of subjects: 80
Study: 20453461

Group type: EXPERIMENTAL
Intervention: HYBT (Hybrid training method)
Number of subjects: 20

Group type: COMPARATOR
Intervention: WMT (Weight machine training)
Number of subjects: 20
Study: 18717680

Group type: EXPERIMENTAL
Intervention: 5-aminolaevulinic acid-photodynamic therapy (ALA-PDT)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Surgical excision (SE)
Number of subjects: 149
Study: 16282192

Group type: EXPERIMENTAL
Intervention: Cannabis-based medicine (Sativex)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 12657409

Group type: EXPERIMENTAL
Intervention: Drägersorb Free
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Amsorb
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Sodasorb II
Number of subjects: 24
Study: 10910489

Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Desflurane
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Thiopental
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control (Thiopental)
Number of subjects: 50
Study: 8840078

Group type: EXPERIMENTAL
Intervention: Telephone engagement intervention (n=54)
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Intensive telephone intervention (n=108)
Number of subjects: 450

Group type: COMPARATOR
Intervention: Business as usual telephone screening (n=108)
Number of subjects: 450
Study: 1389816

Group type: EXPERIMENTAL
Intervention: 0.5% plain bupivacaine administered at a speed of 10 seconds
Number of subjects: 40

Group type: COMPARATOR
Intervention: 0.5% plain bupivacaine administered at a speed of 180 seconds
Number of subjects: 40
Study: 4070430

Group type: EXPERIMENTAL
Intervention: High carbohydrate diet
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low carbohydrate diet
Number of subjects: 12
Study: 30486659

Group type: EXPERIMENTAL
Intervention: Written informational aid (pamphlet)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Standard informed consent discussion (no pamphlet)
Number of subjects: 40
Study: 29162459

Group type: EXPERIMENTAL
Intervention: EEG-neurofeedback training (up-regulation of beta band activity)
Number of subjects: 0

Group type: COMPARATOR
Intervention: EEG-neurofeedback training (down-regulation of beta band activity)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: EEG changes (both up and down regulation)
Number of subjects: 0
Study: 26626719

Group type: EXPERIMENTAL
Intervention: Once-daily tobramycin inhalation solution (TIS) 300 mg/5 mL
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Twice-daily tobramycin inhalation solution (TIS) 300 mg/5 mL
Number of subjects: 29

Group type: COMPARATOR
Intervention: Once-daily versus twice-daily tobramycin inhalation solution (TIS)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Both once-daily and twice-daily tobramycin inhalation solution (TIS)
Number of subjects: 29
Study: 24960387

Group type: EXPERIMENTAL
Intervention: Colgate Plax Magic
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Listerine Cool Blue Agent
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Water and dye
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: Water
Number of subjects: 38

Group type: COMPARATOR
Intervention: Control (no mouthwash)
Number of subjects: 38
Study: 22342106

Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study: 22254024

Group type: EXPERIMENTAL
Intervention: Antioxidant (AO) cocktail (Lactaway(©))
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 16814411

Group type: EXPERIMENTAL
Intervention: Specialist care (cardiology registrar and heart failure nurses)
Number of subjects: 113

Group type: COMPARATOR
Intervention: Control (referred back to general practitioner)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Both groups (specialist care and control)
Number of subjects: 113
Study: 16444386

Group type: EXPERIMENTAL
Intervention: Auto-vacuum device
Number of subjects: 351

Group type: COMPARATOR
Intervention: Syringe pistol holder
Number of subjects: 351